Company Filing History:
Years Active: 2002
Title: Ivan Stamenkovic: Innovator in Immunology
Introduction
Ivan Stamenkovic is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of immunology, particularly through his innovative work on CD40 receptor ligands. With a total of 2 patents, his research has the potential to impact treatments for various autoimmune diseases.
Latest Patents
Stamenkovic's latest patents focus on the development of counter-receptors for the CD40 B-cell antigen. The first patent describes a counter-receptor, termed CD40CR, which includes soluble ligands for this receptor. This invention is based on the discovery that a soluble CD40/immunoglobulin fusion protein can inhibit helper T-cell mediated B-cell activation. The second patent further explores the inhibition of B-cell activation using soluble CD40 or fusion proteins, emphasizing its applications in treating allergies and autoimmune diseases, including graft-versus-host disease and rheumatoid arthritis.
Career Highlights
Ivan Stamenkovic is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research in immunology. His work has garnered attention for its innovative approach to understanding and manipulating immune responses.
Collaborations
Stamenkovic has collaborated with esteemed colleagues such as Alejandro A. Aruffo and Jeffrey A. Ledbetter. These collaborations have contributed to the depth and breadth of his research in the field.
Conclusion
Ivan Stamenkovic stands out as a significant figure in immunology, with his patents paving the way for new therapeutic strategies. His contributions to the understanding of B-cell activation and immune response are invaluable in the ongoing fight against autoimmune diseases.